title: [Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA].
authors.forename: Heiner
authors.initials: H
authors.lastname: Wedemeyer
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.forename: Michael P
authors.initials: MP
authors.lastname: Manns
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage; D002219:Carbamates; D004338:Drug Combinations; D005762:Gastroenterology / Q000592:standards*; D005858:Germany; D006526:Hepatitis C / Q000188:drug therapy* / Q000517:prevention & control*; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D007388:Internal Medicine / Q000592:standards*; D011759:Pyrrolidines; D000069474:Sofosbuvir; D016896:Treatment Outcome; D014542:Uridine Monophosphate / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D014633:Valine / Q000031:analogs & derivatives
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D004338:Drug Combinations; D007093:Imidazoles; D011759:Pyrrolidines; D014542:Uridine Monophosphate; D014633:Valine; C549273:daclatasvir; D000069474:Sofosbuvir